Endovasc Begins Liprostin Pilot Study.Business Editors/Health/Medical Writers MONTGOMERY, Texas--(BUSINESS WIRE)--Jan. 28, 2003 Endovasc Ltd. Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ENVC) -- a biotechnology company focused in the area of cardiovascular disease -- announced today that it received approval from the Food & Drug Administration on Jan. 27 to conduct its Liprostin(TM) Phase II pilot study at the Memorial Hermann Hospital Memorial Hermann Healthcare System is composed of two separate hospital systems which formed in the late 1990s when the Memorial and Hermann systems joined. Both the Memorial and Hermann health care systems started in the early 1900s. in Houston. The study will be conducted by Dr. Richard W. Smalling, professor of medicine of the University of Texas Health Science Center - Memorial Hermann Hospital, on patients who are in the critical phase of peripheral occlusive vascular disease (PAOD PAOD Peripheral Arterial Occlusive Disease ), many of whom face imminent limb amputation amputation (ăm'pyətā`shən), removal of all or part of a limb or other body part. Although amputation has been practiced for centuries, the development of sophisticated techniques for treatment and prevention of infection has greatly or major revascularization surgery. Twelve PAOD patients will be selected for the study to assess the safety and effectiveness of the drug. Enrollment into the study will begin in February. Endovasc encourages patients who suffer from the above condition and desire to be screened for entry into treatment, to have their physician contact Endovasc for referral to Dr. Smalling. According to Dr. David Summers, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Endovasc Ltd. Inc., "This is a very important milestone for our Company. We feel this Phase II pilot study will produce compelling evidence to support the two large scale multinational Phase III trials." Liprostin is a prostaglandin E-1 (PGE-1) hormone stabilized in tiny microspheres called liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. , which the Company believes has the ability to treat the disastrous effects of critical limb ischemia (CLI (1) (Call Level Interface) A database programming interface from the SQL Access Group (SAG), an SQL membership organization. SAG's CLI is an attempt to standardize the SQL language for database access. ), a condition of severe vascular disease that can result in amputation of the limb. Studies have demonstrated that PGE-1 increases blood circulation, prevents platelets from clotting, and reduces leg pain by increasing the oxygen and nutrients in blood-starved muscles. About Endovasc Endovasc Ltd. Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease and pioneering drug-delivery technology that is designed to deliver and release drugs to their intended targets in an efficient and controlled manner. In addition to Liprostin, Endovasc's products include ANGIOGENIX(TM), ProStent(TM) stent-coating technology, biodegradable stents and other drug-delivery stents. The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com. To contact Endovasc regarding treatment in the Phase II pilot study, please call 936/448-2222. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion